Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4152W HIGH $5.78
Volume
2.40 M
Value Traded
9.03 M
Short % Float
11.77%
+6.32%Week
-4.91%1 Month
-13.42%3 Month
+6.61%6 Month
-68.64%5 Year
-62.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
639.48 M
EPS (TTM)
0.79
P/E Ratio
4.92
Ent. Value
560.35 M
Total Shares
165.24 M
Float Shares
159.10 M
Insiders
3.71%
Institutions
98.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IRWD Catalyst Timeline
Dated clinical, regulatory and corporate events for Ironwood Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ironwood Pharmaceuticals, Inc.
389Total events
1Upcoming
130Tier-1 (high impact)
2014 to 2026Coverage
Upcoming catalysts 1
TBD
T2Pipeline Prioritization
Subscribe to view catalyst details
Event history 50
▲Quarterly UpdateCorporate
Ironwood reported Q2 2026 financial results with total revenue of $113 million and GAAP net income of $51 million
◆Management ChangeCorporate
Appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development
●Management ChangeCorporate
Dr. Jeffrey Silber joined Ironwood as Chief Medical Officer and Head of Research and Drug Development
◆Trial InitiationApraglutideTrial
Initiate confirmatory Phase 3 trial of apraglutide for SBS-IF
short bowel syndrome with intestinal failure (SBS-IF)source ↗
◆Oral PresentationPresentation
Ironwood Pharmaceuticals to participate in Jefferies Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
▲Debt Royalty FinancingCorporate
Ironwood repaid $200 million aggregate principal amount of 1.50% convertible senior notes at maturity
▲FDA ApprovalLINZESSApprovedFDA Decision
FDA approves LINZESS for pediatric FC patients aged 2+
functional constipation (FC) in pediatric patients two years of age and oldersource ↗
◆PDUFA DateLINZESSApprovedRegulatory Filing
PDUFA date set for May 24, 2026 for LINZESS sNDA
functional constipation (FC) in patients 2 to 5 years of agesource ↗
▲FDA Filing AcceptedLINZESSApprovedRegulatory Filing
sNDA for LINZESS in FC pediatric patients 2-5 years accepted and granted priority review by FDA
functional constipation (FC) in patients 2 to 5 years of agesource ↗
●Oral PresentationPresentation
Survey findings presented at DDW 2026
Short Bowel Syndrome (SBS)source ↗
◆Oral PresentationPresentation
Presentation of LANDMARK survey data on HCP perspectives on TPN burden in SBS at DDW 2026
Short Bowel Syndrome (SBS)source ↗
●Oral PresentationApraglutidePresentation
Ironwood presented pooled apraglutide data from STARS clinical program at 2026 Digestive Disease Week
short bowel syndrome with intestinal failure (SBS-IF)source ↗
▲FDA ApprovalLINZESSApprovedFDA Decision
FDA approved LINZESS for pediatric patients 2 years and older with functional constipation
functional constipation (FC) in pediatric patients 2 years of age and oldersource ↗
●Management ChangeCorporate
Ronald Silver appointed Interim Chief Financial Officer following resignation of Gregory Martini
▲Trial InitiationApraglutideTrial
Ironwood initiated STARS-2 confirmatory Phase 3 trial of apraglutide in SBS-IF and is actively recruiting patients
short bowel syndrome with intestinal failure (SBS-IF)source ↗
◆Quarterly UpdateCorporate
Provide details on apraglutide trial design in Q4 and full-year 2025 update
◆Quarterly UpdateCorporate
Q4 and full-year 2025 update with details on apraglutide trial design
▲FDA Filing AcceptedLINZESSApprovedRegulatory Filing
FDA accepted sNDA for LINZESS for FC in patients 2-5 years and granted priority review
functional constipation (FC) in patients 2 to 5 years of agesource ↗
◆Trial InitiationApraglutideTrial
Initiation of Phase 3 confirmatory study for apraglutide
short bowel syndromesource ↗
▲Priority ReviewLINZESSApprovedRegulatory Filing
Priority review granted for LINZESS sNDA
functional constipation (FC) in patients 2 to 5 years of agesource ↗
◆FDA Feedback ReceivedApraglutideFDA Meeting
FDA alignment on Phase 3 confirmatory trial design for apraglutide
short bowel syndromesource ↗
▲FDA ApprovalLINZESSApprovedFDA Decision
FDA approval of LINZESS for IBS-C in pediatric patients 7 years and older
irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and oldersource ↗
▲FDA Feedback ReceivedApraglutideFDA Meeting
FDA meeting to align on confirmatory Phase 3 trial design of apraglutide for SBS-IF
short bowel syndrome with intestinal failure (SBS-IF)source ↗
●Timing GuidanceApraglutidePresentation
Rolling NDA submission on track to be completed in Q3 2025
short bowel syndromesource ↗
●Quarterly UpdateCorporate
Reiterates full-year 2025 LINZESS U.S. net sales guidance of $800-$850 million and total Ironwood revenue of $260-$290 million
▼Program DiscontinuationApraglutideCorporate
No longer plan to make certain apraglutide commercial launch planning investments; shift focus to confirmatory Phase 3 trial
short bowel syndromesource ↗
◆FDA Feedback ReceivedApraglutideFDA Meeting
Recent FDA feedback received regarding apraglutide confirmatory Phase 3 trial
short bowel syndromesource ↗
▼FDA Feedback ReceivedApraglutideFDA Meeting
FDA feedback indicates confirmatory Phase 3 trial needed for apraglutide approval
short bowel syndrome with intestinal failure (SBS-IF)source ↗
▼Quarterly UpdateCorporate
Received Nasdaq non-compliance notice for late 2024 Form 10-K filing
●Rolling Submission InitiatedApraglutideRegulatory Filing
Rolling NDA submission initiated for apraglutide
short bowel syndromesource ↗
▲Full ResultsApraglutideClinical Data
Positive data from open-label extension study showing increased number of patients achieving enteral autonomy over time
short bowel syndromesource ↗
▲Quarterly UpdateCorporate
LINZESS EUTRx prescription demand growth in Q1 2025 of 8% year-over-year
◆Timing GuidanceApraglutidePresentation
Plans to pursue apraglutide rolling NDA review; expects to complete submission in Q1 2025
short bowel syndrome with intestinal failuresource ↗
▼Trial DiscontinuedTrial
Ironwood ends further recruitment for Phase II IC/BPS study
interstitial cystitis/bladder pain syndrome (IC/BPS)source ↗
▲Topline ReadoutApraglutideClinical Data
Positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with SR GI aGVHD
steroid-refractory gastrointestinal acute Graft-versus-Host Diseasesource ↗
◆Topline ReadoutApraglutideClinical Data
Topline data from STARS Phase 3 study of apraglutide in SBS-IF
short bowel syndrome with intestinal failure (SBS-IF)source ↗
Past FDA Catalysts and PDUFA Decisions
How IRWD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-27 | LINZESS (linaclotide) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$266M
Pipeline Value
$891M
Commercial Value
Undervalued
Valuation Signal
5
Drugs Scored
1.4x
rNPV / MCap
Top 36%
Micro Cap(rank 238 of 658)
Percentile Rank
Ironwood Pharmaceuticals, Inc. carries a moderate pipeline score (41/100), with $666M risk-adjusted pipeline value, led by Apraglutide in Hepatic Impairment (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $389.3M x 2.3 = $891M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apraglutide Small moleculeNCT05018286 | Short Bowel Syndrome | Phase 3 | ACTIVE NOT_RECRUITING | 456 | Oct 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every IRWD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| apraglutide | short bowel syndrome with intestinal failure | Phase 3 | 2024-05-09 | In the Phase III STARS trial, once-weekly apraglutide demonstrated significant efficacy in adults with short bowel syndrome, showing a positive response rate and validating its potential as the first GLP-2 analog for patients dependent on parenteral support.Read More | Ironwood Pharmaceuticals Reports First Quarter 2024 Results - Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Silver RonaldOfficer (PFO & PAO) | Sell | -127,890 313,680 held | $4.52 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IRWD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 0.5 % (25 %) | 7.16 M | 5.47 M |
IRWD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IRWD ranks across every disease it competes in
Competitive Position is a premium feature
See how IRWD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIRWD News
IRWDIronwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals will participate in the Wells Fargo 21st Annual Healthcare Conference on September 10th at 10:15 a.m. ET. The event will feature a fireside chat with management, and a live webcast will be available on the company's website. A replay of the webcast will also be accessible post-conference.
Read more →IRWDIronwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Ironwood Pharmaceuticals has reported strong second quarter results for 2026, leading to an increase in its full-year financial guidance. The company emphasizes its commitment to maximizing LINZESS, advancing apraglutide, and achieving sustained profitability. This performance reflects their strategic focus and execution in the biotechnology sector.
Read more →IRWD▲ +13.4%on this news
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals has announced its second quarter 2026 investor update call, scheduled for August 6, 2026, at 8:30 a.m. Eastern Time. The call will be accessible via phone and webcast, demonstrating the company's commitment to investor relations. Participants can join using specific dial-in numbers and a conference ID.
Read more →IRWD▼ -5.5%on this news
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Ironwood Pharmaceuticals has announced the retirement of Dr. Michael Shetzline as Chief Medical Officer, appointing Dr. Jeffrey Silber as his successor. Dr. Silber will lead the company's Research and Drug Development efforts. Additionally, the STARS-2 trial has been initiated and is currently recruiting patients, highlighting Ironwood's ongoing commitment to advancing therapies for gastrointestinal and rare diseases.
Read more →IRWDIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2026
Ironwood Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 4, 2026, with a fireside chat scheduled for 11:05 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Ironwood is known for developing therapies for gastrointestinal and rare diseases.
Read more →IRWDIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Ironwood Pharmaceuticals is set to participate in the Jefferies Global Healthcare Conference. This event will provide a platform for the company to discuss its strategies and developments in the healthcare sector. Further details about the conference and Ironwood's agenda have not been disclosed.
Read more →IRWDFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
The FDA has approved LINZESS® (linaclotide) for use in pediatric patients aged two years and older who suffer from functional constipation. This approval provides a new treatment option for a condition that can significantly impact children's quality of life. The decision reflects the growing recognition of the need for effective therapies in younger populations.
Read more →IRWD▼ -13.7%on this news
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Pharmaceuticals reported a strong first quarter for 2026, with total revenue reaching $106.5 million, a significant increase from $41.1 million in the same period last year. The company attributes this growth primarily to a 97% rise in LINZESS U.S. net sales, driven by improved pricing and prescription demand. Ironwood also remains on track to initiate the STARS-2 Phase 3 clinical trial for apraglutide, which aims to redefine treatment standards for short bowel syndrome.
Read more →IRWD▼ -13.7%on this news
Ironwood Pharmaceuticals Reports Strong First
Ironwood Pharmaceuticals has reported strong financial results for Q1 2026, highlighting a 97% year-over-year increase in U.S. net sales for LINZESS, totaling $273 million. The company's total revenue reached $107 million, indicating significant business performance. Notably, Ironwood is on track to initiate site operations for a Phase 3 trial of apraglutide in treating short bowel syndrome and has received FDA priority review for a supplemental NDA related to LINZESS for younger patients. Overall, Ironwood maintains confidence in its full-year financial guidance.
Read more →IRWDIronwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood's survey findings presented at DDW 2026 highlight the complexities surrounding Total Parenteral Nutrition (TPN) in patients with Short Bowel Syndrome (SBS). The data emphasizes the necessity for therapies that can effectively address the multifaceted burdens associated with TPN. This underscores the ongoing challenges faced by patients and the need for innovative solutions in their treatment.
Read more →IRWDIronwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals has announced an investor update conference call scheduled for May 7, 2026. The call will provide insights into the company's developments and future plans. Participants can join via phone or webcast, with replays available shortly after the call. Ironwood continues to focus on innovative therapies for gastrointestinal and rare diseases.
Read more →IRWD▼ -9.3%on this news
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Ironwood Pharmaceuticals will present findings from its LANDMARK survey at the 2026 Digestive Disease Week. The focus will be on healthcare professionals' perspectives regarding the burden of total parenteral nutrition in patients with short bowel syndrome. This presentation aims to shed light on critical insights that could influence treatment approaches.
Read more →IRWDIronwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Ironwood Pharmaceuticals will participate in The Citizens Life Sciences Conference, emphasizing its commitment to advancing gastrointestinal healthcare. The company's mission is to redefine the standard of care for patients suffering from GI diseases. This participation showcases Ironwood's role in the healthcare landscape.
Read more →IRWD▲ +8.9%on this news
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
Ironwood Pharmaceuticals reported strong financial results for 2025, achieving $296 million in revenue and a GAAP net income of $24 million. The company expects continued growth for LINZESS and has finalized the design for a Phase 3 clinical trial of apraglutide in short bowel syndrome. Ironwood is well-positioned for 2026 with a projected adjusted EBITDA exceeding $300 million.
Read more →IRWDIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the fourth quarter and full year of 2025. This call aims to provide shareholders with insights into the company's financial performance and strategic direction. The event underscores Ironwood's commitment to maintaining open communication with its investors.
Read more →IRWD▲ +7.5%on this news
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals has announced its financial guidance for FY 2026, projecting U.S. net sales of LINZESS between $1.125 to $1.175 billion and total revenues of $450 to $475 million. The company ended Q4 2025 with over $200 million in cash and plans to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026. CEO Tom McCourt emphasized the focus on maximizing LINZESS and advancing apraglutide while maintaining financial stability.
Read more →About Ironwood Pharmaceuticals, Inc.
Headquarters100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE PLUS
Trade the next IRWD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime